NewAmsterdam Pharma Company N.V. (NAMS)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-18) · 99.1 | 8-K (2026-01-09) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-05) · 99.1 · 99.2 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-06) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-26) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 20-F/A | FY-2022 | |||
| 10-Q | Q2-2024 | 8-K (2024-08-07) · 99.1 | 8-K (2024-05-09) · 99.1 | ||
| 10-Q | Q1-2024 | — | ||
| 10-K | FY-2023 | 8-K (2024-02-28) |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Condensed Balance Sheets (P) | — |
|
| Condensed Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Operations and Comprehensive Income (loss) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Shareholders' Equity (deficit) | — |
|
| Consolidated Statements of Mezzanine Equity and Shareholders' Equity (deficit) | ||
| Consolidated Statements of Shareholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Expenses and Other Current Liabilities | ||
| Award Timing Disclosure | — |
|
| Benefit Plan | — |
|
| Cash, Cash Equivalents and Marketable Securities | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Fair Value Measurements | ||
| Flac Merger | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Net Loss Per Ordinary Share | ||
| Pay Vs Performance Disclosure | ||
| Prepayments and Other Receivables | ||
| Related Parties | ||
| Revenue | ||
| Segment Information | ||
| Share-based Compensation | ||
| Shareholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| The Company | ||